Collaborative arrangement revenues and expense sharing percentage.

No definition available.

Name:	plx_CollaborativeArrangementRevenuesExpensesSharingPercentage
Namespace Prefix:	plx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

The Amended Pfizer Agreement eliminates Pfizer's entitlement to annual payments in relation to commercialization of Elelyso in Brazil.

+ References

No definition available.

+ Details

Name:	plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfitsEliminationAmount
Namespace Prefix:	plx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Pursuant to the Amended Pfizer Agreement, the Company sold to Pfizer its share in the collaboration created under the initial Pfizer Agreement for the commercialization of Elelyso in exchange for a cash payment amount.

+ References

No definition available.

+ Details

Name:	plx_ProceedsFromSaleOfShareInCollaboration
Namespace Prefix:	plx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

As part of the Stock Purchase Agreement, Pfizer has agreed to a lock-up period with respect to the purchased shares of common stock.

+ References

No definition available.

+ Details

Name:	plx_StockPurchaseAgreementLockUpPeriod
Namespace Prefix:	plx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Face (par) amount of debt instrument at time of issuance.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

+ Details

Name:	us-gaap_DebtInstrumentFaceAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(2))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_DebtInstrumentMaturityDate
Namespace Prefix:	us-gaap_
Data Type:	xbrli:dateItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

+ Details

Name:	us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.

+ References

No definition available.

+ Details

Name:	us-gaap_SubsequentEventLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=plx_PfizerIncorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TitleOfIndividualAxis=us-gaap_ExecutiveOfficerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementGeographicalAxis=plx_ExcludingBrazilMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementGeographicalAxis=country_BR
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DebtInstrumentAxis=plx_October2015PromissoryNoteToPfizerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

SUBSEQUENT EVENTS (Details) - USD ($) $ in Millions	1 Months Ended
SUBSEQUENT EVENTS (Details) - USD ($) $ in Millions	Oct. 31, 2015	Sep. 30, 2015
Pfizer Agreement [Member] \| Pfizer Incorporation [Member]
Subsequent Event [Line Items]
Agreement, future revenues and expenses sharing percentage		60.00%
Pfizer Agreement [Member] \| Protalix Bio Therapeutics Incorporation [Member]
Subsequent Event [Line Items]
Agreement, future revenues and expenses sharing percentage		40.00%
Subsequent Event [Member]
Subsequent Event [Line Items]
Common stock issued	5,649,079
Common stock issued, value	$ 10.0
Subsequent Event [Member] \| Directors and Executive Officers [Member]
Subsequent Event [Line Items]
Lock-up period with respect to the purchased shares of common stock	90 days
Subsequent Event [Member] \| Pfizer Incorporation [Member]
Subsequent Event [Line Items]
Lock-up period with respect to the purchased shares of common stock	180 days
Subsequent Event [Member] \| Amended Pfizer Agreement [Member]
Subsequent Event [Line Items]
Proceeds from sale of share in the collaboration created under the initial Pfizer Agreement for the commercialization of Elelyso	$ 36.0
Subsequent Event [Member] \| Amended Pfizer Agreement [Member] \| Pfizer Incorporation [Member] \| Excluding Brazil [Member]
Subsequent Event [Line Items]
Agreement, future revenues and expenses sharing percentage	100.00%
Subsequent Event [Member] \| Amended Pfizer Agreement [Member] \| Protalix Bio Therapeutics Incorporation [Member]
Subsequent Event [Line Items]
License and supply agreement potential future payment, elimination amount	$ 12.5
Subsequent Event [Member] \| Amended Pfizer Agreement [Member] \| Protalix Bio Therapeutics Incorporation [Member] \| BRAZIL
Subsequent Event [Line Items]
Agreement, future revenues and expenses sharing percentage	100.00%
Subsequent Event [Member] \| Amended Pfizer Agreement [Member] \| October 2015 Promissory Note To Pfizer [Member]
Subsequent Event [Line Items]
Promissory note, amount	$ 4.2
Maturity date	Oct. 31, 2020